title: Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.
abstract: Improvements in technology and resources are helping to advance our understanding of cancer-initiating events as well as factors involved with tumor progression, adaptation, and evasion of therapy. Tumors are well known to contain diverse cell populations and intratumor heterogeneity affords neoplasms with a diverse set of biologic characteristics that can be used to evolve and adapt. Intratumor heterogeneity has emerged as a major hindrance to improving cancer patient care. Polygenic cancer drug resistance necessitates reconsidering drug designs to include polypharmacology in pursuit of novel combinatorial agents having multitarget activity to overcome the diverse and compensatory signaling pathways in which cancer cells use to survive and evade therapy. Advances will require integration of different biomarkers such as genomics and imaging to provide for more adequate elucidation of the spatially varying location, type, and extent of diverse intratumor signaling molecules to provide for a rationale-based personalized cancer medicine strategy.
authors: Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109-2200, USA. alnawaz@umich.edu
authors: Alnawaz
authors: A
authors: Rehemtulla
mesh_terms: D014408:Biomarkers, Tumor; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010506:Periodicals as Topic; D011643:Publishing; D011859:Radiography; D011877:Radionuclide Imaging
chemical_list: D014408:Biomarkers, Tumor